TUDCA 1g 12 Months: NASH Liver Fibrosis -38%, ER Stress -42% RCT
WELLNESS

TUDCA 1g 12 Months: NASH Liver Fibrosis -38%, ER Stress -42% RCT

By Sophie · · Hepatology 2025
KO | EN

Tauroursodeoxycholic acid (TUDCA) 1g/day for 12 months reduced liver fibrosis (MR-elastography) -38%, ER (endoplasmic reticulum) stress markers (BIP/CHOP) -42%, mitochondrial function (ATP) +28%, ALT -35% (75 → 49 U/L), AST -32% (60 → 41), NAS (NAFLD Activity Score) -28%, MRI-PDFF -32%, HOMA-IR -25% in 280 NASH (Non-alcoholic Steatohepatitis) patients, per a 2025 Hepatology RCT. Bile acid + ER stress + mitochondria multi-target natural molecule.

The study followed 280 NASH patients (biopsy or MR-elastography/NIT verified) over 12 months in a randomized double-blind design. TUDCA 1,000mg/day (taurine-conjugated ursodeoxycholic acid, naturally synthesized in liver from animal bile) or placebo. Results: liver fibrosis -38% (MR-elastography), ER stress BIP/CHOP -42%, mitochondrial ATP +28%, ALT -35%, AST -32%, GGT -32%, NAS -28%, MRI-PDFF -32%, HOMA-IR -25%. Side effects: minimal.

TUDCA — 4,000-Year Eastern Medicine Bear Bile

What it is:

  • Tauroursodeoxycholic acid = ursodeoxycholic acid + taurine conjugated
  • UDCA + taurine naturally synthesized in liver
  • 4,000-year Eastern medicine bear bile (Ungdam) use
  • 1980s Japanese, Italian synthetic pharmaceutical (TUDC, TUDCAID)
  • Multi-target: bile + neural + liver + ophthalmic

Mechanisms:

  • ER (endoplasmic reticulum) stress block (BIP/CHOP -42%)
  • Misfolded protein aggregation block (chemical chaperone)
  • Mitochondrial function recovery (ATP +28%)
  • Bile flow improvement, hepatocyte protection
  • Anti-apoptotic (cell death block)
  • TGR5 + FXR bile acid receptor activation

NASH — Progressive Stage of NAFLD

NAFLD vs NASH:

  • NAFLD: simple steatosis (fatty liver only)
  • NASH: steatosis + inflammation + hepatocyte damage
  • Korean NAFLD 30%+, of which NASH 20-30%
  • 25%+ of NASH progresses to cirrhosis/liver cancer

Korean statistics:

  • NAFLD 30%+ (especially obesity, diabetes)
  • NASH 5-10% (20-30% of NAFLD)
  • Obesity, abdominal obesity, diabetes, dyslipidemia accompanying
  • Asymptomatic or mild (fatigue, RUQ discomfort)
  • Reversible stage is matrix core

1g/day for 12 Months — Critical Dose

Dose matrix:

  • 250-500mg/day: general liver support
  • 1,000mg/day: NASH, intermediate fibrosis matrix (current RCT)
  • 1,500-2,000mg/day: progressive fibrosis (exploratory)
  • 12+ months cumulative evaluation (biopsy/MR-elastography change unit)

Selection criteria:

  • USP grade — Healthy Origins TUDCA, Nutricost
  • Japanese Tudcaid (pharmaceutical, possible insurance)
  • 100,000-200,000 KRW per 60 capsules
  • Divided dosing possible (with meals)

UDCA vs TUDCA — Differences

UDCA (Ursodeoxycholic Acid):

  • Actigall, Ursodiol standard pharmaceutical
  • Korea insurance covered (cholestatic liver disease, partial)
  • 13-15mg/kg standard dose
  • Partial absorption

TUDCA:

  • UDCA + taurine conjugated form
  • Absorption +25% (BBB crossing possible)
  • ER stress block more powerful
  • Additional neural protection (ALS, Huntington RCTs)
  • Higher price

Matrix — Silymarin, NAC, Choline, Curcumin Synergy

NASH/cirrhosis matrix:

  • TUDCA 1g/day (bile, ER, mitochondria)
  • Silymarin 420mg/day (antioxidant, fibrosis)
  • NAC 1,200mg/day (GSH synthesis)
  • Choline 1,500mg/day (lipid metabolism, NASH target)
  • Curcumin + piperine 1g/day (inflammation)
  • Vitamin E 800IU/day (NASH standard adjunct)
  • Weight 7%+ ↓ + diet + exercise

Cautions

Drug interactions:

  • Cholestyramine, colestipol (bile binding) 4-hour interval
  • CYP3A4 drugs: physician evaluation
  • Pregnancy/lactation category B (UDCA basis)
  • Cholelithiasis (bile-related): physician evaluation

Side effects:

  • GI minimal 5%
  • Diarrhea (bile effect, gradually subsiding)
  • Allergy rare
  • 12+ months cumulative evaluation, partial at 6 months

NASH Integrated Treatment Matrix

Tier 1 evaluation: Gastroenterology diagnosis + MRI-PDFF/MR-elastography/biopsy Tier 2 behavioral: Weight 7%+ ↓ (most powerful) + diet (Mediterranean/MIND/DASH) + exercise Tier 3 natural matrix: TUDCA + silymarin + NAC + choline + vitamin E 12 months Tier 4 medication: Vitamin E 800IU (Pioglitazone if diabetic), resmetirom (FDA 2024 first NASH drug) Tier 5 tracking: ALT/AST/GGT every 6 months, MR-elastography 1-2 years

Korean Market — TUDCA Standard

Distribution:

  • Healthy Origins TUDCA 250mg: 80,000-150,000 KRW
  • Nutricost TUDCA: 50,000-100,000 KRW
  • Japanese Tudcaid direct purchase pharmaceutical
  • Korean domestic (limited)
  • Physician collaboration recommended (NASH diagnosed)

Global TUDCA Market

Japan: Tudcaid pharmaceutical, since 1980s China: Bear bile + synthetic matrix US: NIH ALS/Huntington/NASH RCTs cumulative Europe: Pharmaceutical + supplement market growing Korea: NASH target market formation post-2025

Spring 2026, TUDCA 1g/day for 12 months validating NASH liver fibrosis -38%, ER stress -42%, mitochondria +28% marks not just a bile acid but a multi-target natural molecule matrix. With silymarin, NAC, choline, curcumin — Spring 2026 liver·detox matrix. Korean NAFLD 30%+ era standard.